The efficacy and toxicity of cabazitaxel for treatment of docetaxel-resistant prostate cancer correlating with the initial doses in Japanese patients | BMC Cancer | Full Text
ASCO 2022: 177Lu-PSMA-617 (LuPSMA) Versus Cabazitaxel in mCRPC Progressing After Docetaxel—Overall Survival After Median Follow-Up of 3 Years (ANZUP 1603) - TheraP
ASCO 2022: TheraP: 177Lu-PSMA-617 (LuPSMA) Versus Cabazitaxel in Metastatic Castration-Resistant Prostate Cancer (McRpc) Progressing After Docetaxel—Overall Survival After Median Follow-Up of 3 Years (ANZUP 1603)
Impact of cabazitaxel on 2-year survival and palliation of tumour-related pain in men with metastatic castration-resistant prostate cancer treated in the TROPIC trial - ScienceDirect
Therapeutic Outcome of >10 Cycles of Cabazitaxel for Castration-resistant Prostate Cancer: A Multi-institutional Study | Anticancer Research
Cabazitaxel plus carboplatin for the treatment of men with metastatic castration-resistant prostate cancers: a randomised, open-label, phase 1–2 trial - The Lancet Oncology
ASCO 2022: TheraP: 177Lu-PSMA-617 (LuPSMA) Versus Cabazitaxel in Metastatic Castration-Resistant Prostate Cancer (McRpc) Progressing After Docetaxel—Overall Survival After Median Follow-Up of 3 Years (ANZUP 1603)
Efficacy of cabazitaxel and the influence of clinical factors on the overall survival of patients with castration‐resistant prostate cancer: A local experience of a multicenter retrospective study - Takai - 2021 -
Overall and progression-free survival with cabazitaxel in metastatic castration-resistant prostate cancer in routine clinical practice: the FUJI cohort | British Journal of Cancer
Cabazitaxel for the treatment of castration-resistant prostate cancer | Future Oncology
Cabazitaxel versus Abiraterone or Enzalutamide in Metastatic Prostate Cancer | NEJM
Overall and progression-free survival with cabazitaxel in metastatic castration-resistant prostate cancer in routine clinical practice: the FUJI cohort | British Journal of Cancer
Kaplan–Meier curves of overall survival by treatment group (TROPIC... | Download Scientific Diagram
Real-world efficacy and safety of two doses of cabazitaxel (20 or 25 mg/m2) in patients with castration-resistant prostate cancer: results of a Japanese post-marketing surveillance study | BMC Cancer | Full Text
Overall survival (OS) after cabazitaxel treatment. a OS in the... | Download Scientific Diagram
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial - The Lancet
a) Progression free survival (PFS) on cabazitaxel (CAB) as 2 nd or... | Download Scientific Diagram
Real-world effectiveness of third-line cabazitaxel in patients with metastatic castration-resistant prostate cancer: CARD-like analysis of data from a post-marketing surveillance in Japan | BMC Cancer | Full Text
Indirect treatment comparison of cabazitaxel for patients with metastatic castrate-resistant prostate cancer who have been previously treated with a docetaxel-containing regimen | PLOS ONE
Choosing Chemotherapy for Castration-Resistant Prostate Cancer
Cabazitaxel Superior to Switching Antiandrogens for Third-Line mCRPC Treatment - Renal and Urology News
Serum and hematologic responses after three cycles of cabazitaxel therapy as predictors of survival in castration-resistant prostate cancer | SpringerLink
Efficacy of Cabazitaxel Treatment in Metastatic Castration Resistant Prostate Cancer in Second and Later Lines. An Experience from Two German Centers
Optimal Timing of Cabazitaxel Introduction for Japanese Patients With Metastatic Castration-resistant Prostate Cancer | Anticancer Research
